PLAINSBORO, N.J., United States -- Novo Nordisk announced that the US Food and Drug Administration has approved Awiqli® injection, indicated to improve glycemic control (blood sugar) in adults living with type 2 diabetes, sets the world record as the First Once-Weekly Insulin for Type 2 Diabetes.